April 2023 Investor Newsletter

April 2023 Investor Newsletter

We are continuing the momentum from our positive phase 1 trial results and are pleased to have recently released our latest updates in our April Investor Newsletter covering:

🔹 Clinical data and expert review triggers commercial partner outreach efforts
🔹 MRI utility drives new IP and AI/ML efforts
🔹 Upcoming events and a recap on key media coverage

Read the full newsletter: HERE >> 




Questions about this announcement or other investor-related inquiries? Please email our investor relations department at: investor@imagionbio.com.

Related Articles

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.